Al Mattar Eman, Al Sharidah Sondus, Hashem Omnia A
Pediatric Hematology/Oncology and Stem Cell Transplant Unit, NBK Specialized Children's Hospital, Kuwait City, Kuwait.
Cancer Rep (Hoboken). 2025 Aug;8(8):e70293. doi: 10.1002/cnr2.70293.
Chemotherapy-induced peripheral polyneuropathy (CIPN) is a debilitating side effect of cancer treatment such as in acute lymphoblastic leukemia (ALL). Characterized by the dysfunction of the peripheral nervous system, CIPN can occur in 90% of pediatric patients, significantly impairing their quality of life. In most cases, it necessitates the modification of standard chemotherapy regimens, which can compromise the treatment efficacy and increase the risk of relapse.
We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.
Early recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.
化疗引起的周围性多发性神经病(CIPN)是癌症治疗(如急性淋巴细胞白血病(ALL))中一种使人衰弱的副作用。CIPN以外周神经系统功能障碍为特征,可发生在90%的儿科患者中,严重损害他们的生活质量。在大多数情况下,这需要修改标准化疗方案,而这可能会影响治疗效果并增加复发风险。
我们报告一名16岁患ALL的男孩,他在诱导治疗期间发生了CIPN。多学科、个体化的治疗方法结合定期随访确保了最佳管理。患者实现了完全缓解,活动能力和神经功能有显著改善。
对儿科ALL患者的CIPN进行早期识别和综合管理对于优化治疗结果同时维持化疗的整体疗效至关重要。